Objectives-This pilot study compared contrast enhanced ultrasound (US) with contrast-enhanced magnetic resonance imaging (MRI) in assessing the treatment response in patients with breast cancer receiving preoperative neoadjuvant chemotherapy (NAC).
burden affecting the skin or pectoralis muscle. However, there is no significant difference in overall survival in patients receiving adjuvant chemotherapy or NAC. 1, 2 With new advances, NAC has become more successful in achieving a complete pathologic response, which is associated with better overall survival. 2, 3 The rates of a complete pathologic response vary and are dependent on the breast cancer subtype 4 and the definition of complete pathologic response used. For this study, a complete pathologic response was defined as the absence of any residual invasive or in situ disease within the breast. Lymph node status was not included. 5 Accurate prediction of the tumor response to chemotherapy by imaging is important for determining the type of surgery needed (breast-conserving surgery versus mastectomy). Physical examination, mammography, and conventional ultrasound (US) imaging are limited in assessing tumor size after NAC, since they do not provide functional information, and adequate tumor evaluation is often confounded by adjacent tissues, edema, and fibrosis. 6 The existing literature supports magnetic resonance imaging (MRI) as the best tool for assessing the tumor response to NAC. In a meta-analysis of 300 patients comparing agreement between MRI and tumor size at surgery after NAC, MRI's performance was generally superior to that of mammography, US, and clinical examination. 7 The paramagnetic contrast medium in breast MRI is used to examine the vascularity and angiogenesis within the tumor. 8, 9 However, MRI after NAC can overestimate 10 and underestimate the extent of the residual tumor. 2, 11 Contrast-enhanced US, as does MRI, provides both morphologic and functional information. The contrast agent shows vascularity within the tumor and may distinguish between posttreatment fibrosis (no enhancement) and an active residual tumor (enhancement) after NAC. Unlike gadolinium-based agents in MRI, which diffuse from the blood vessels into adjacent interstitial tissues, microbubble agents in contrast-enhanced US stay within the blood vessels. Contrast-enhanced US has been used to classify benign and malignant tumors in abdominal imaging, and current studies are investigating contrastenhanced US in evaluating breast masses. Corcioni et al 12 reported a good correlation between timeintensity curves comparing contrast-enhanced US with MRI for 16 women with large or locally advanced breast cancers undergoing NAC.
The purpose of this pilot study was to compare contrast-enhanced US with MRI in assessing the tumor size and pathologic response in patients with breast cancer receiving preoperative NAC.
Materials and Methods

Patients
From January 2014 to October 2015, 30 female patients (18 years) with a diagnosis of invasive breast cancer of greater than 2 cm and scheduled to receive NAC were included in this Institutional Review Board-approved and Health Insurance Portability and Accountability Act-compliant prospective study. Written informed consent was obtained. Exclusion criteria included women who were pregnant or had a history of breast cancer in the same breast, open surgical biopsy for breast cancer diagnosis, a cardiac shunt, pulmonary hypertension, or hypersensitivity to the perflutren agent. All patients had invasive ductal carcinoma, except for 1 patient with metaplastic carcinoma. Diagnoses were based on clinical examination, mammography, and conventional US imaging and confirmed with percutaneous core needle biopsy. Only the largest biopsy-proven tumor was used for analysis if the patient had multifocal or multicentric disease. The baseline pretreatment tumor size (longest dimension) on conventional US imaging had a median of 3.3 cm. The chemotherapy regimens were not specified by the study design, but each patient had a treatment plan with a primary cytotoxic agent as a key component. After completion of NAC, patients had breast-conserving surgery or mastectomy based on a posttreatment physical examination, imaging findings, and discussion between the patient and surgeon.
Conventional and Contrast-Enhanced US Protocols
Contrast-enhanced US examinations were performed on an Epiq US machine (Philips Healthcare, Bothell, WA) with a linear transducer (12 MHz) or curvilinear transducer (9 MHz) to maximize lesion visibility, depending on the size and depth of the tumor. The breast was first scanned with conventional B-mode US to identify the tumor and determine its longest dimension. This procedure was followed by real-time contrast-enhanced US imaging using a low mechanical index (automatically selected by the machine in the contrast-enhanced US mode) ranging between 0.06 and 0.08. The contrast agent Definity (perflutren lipid microspheres; Lantheus Medical Imaging, North Billerica, MA) was agitated per protocol, and 10 lL/kg was administered through an 18-gauge catheter placed in an antecubital vein. The agent was injected as a single intravenous bolus, followed by a 10-mL saline flush (0.9% sodium chloride). Definity is approved by the US Food and Drug Administration for use in cardiac studies and for off-label use in the breast. Images were recorded with a clip function for 90 seconds after administration of the contrast agent while the transducer was stabilized with minimal pressure. A qualitative evaluation of tumor enhancement was performed. The presence of contrast uptake within the tumor was categorized as none, minimal, or avid. At a later time, postprocessing analysis of the data was performed with Philips QLAB software, in which regions of interest (ROIs) were placed in the most representative portion of the tumor and in normal adjacent breast tissue. QLAB plotted the dynamic echo mean of the ROI as a function of time and then fit the data to a wash-in/ wash-out curve. From these time/signal intensity curves, quantitative blood perfusion parameters, including peak intensity and wash-in slope, were generated for both the tumor and adjacent background breast tissue. Tumor measurements were made by a dedicated breast imager with greater than 15 years of experience, who was blinded to the MRI results and surgical data. The largest dimension of tumor size was used for data analysis. Tumor necrosis (divided into quartiles 0%-25%, 26%-50%, 51%-75%, and 76%-100%) was subjectively determined while the contrast-enhanced US images were reviewed. We attempted to perform the baseline and post-NAC treatment contrast-enhanced US scans on the same day as the corresponding MRI. Due to limitations of patient scheduling, sometimes the contrast-enhanced US and MRI scans were performed on different days. The median number of days the posttreatment contrastenhanced US scans were performed was 13 days before surgery.
Magnetic Resonance Imaging
Dynamic contrast-enhanced MRI was performed with a 1.5-T Excite HD machine (GE Healthcare, Waukesha, WI) or a 1.5-T Symphony machine (Siemens Medical Solutions, Mountain View, CA) with a dedicated breast coil. A bolus of a gadolinium-based contrast agent (gadopentetate dimeglumine, 0.1 mmol/kg) was injected at a rate of 3 mL/s. The MRI protocol included axial and coronal short-tau inversion recovery images, a precontrast T1-weighted acquisition, and additional postcontrast T1-weighted acquisitions obtained up to 5 to 7 minutes after the administration of the contrast agent. A postprocessing analysis of the MRI data was performed with CADstream software (Merge Healthcare, Inc, Chicago, IL) to generate subtractions and dynamic time/signal intensity curves. The quantitative parameter of highest tumor enhancement at 1 minute was obtained by drawing an ROI around the tumor. Tumor measurements were made by 2 dedicated breast imagers, who were blinded to the results of the contrast-enhanced US and surgical data. The largest dimension of the tumor diameter was used for analysis. Tumor necrosis (divided into quartiles 0%-25%, 26%-50%, 51%-75%, and 76%-100%) was subjectively determined after reviewing the MR images. The median number of days the posttreatment MRI scans were performed was 32 days before surgery.
Surgical Pathologic Examinations
The contrast-enhanced US and MRI findings after completion of NAC were compared with the pathologic tissue specimens obtained from definitive surgical treatment (breast-conserving surgery or mastectomy). At our institution, surgery is usually performed 4 to 6 weeks after the completion of NAC. The presence or absence of residual invasive and in situ carcinoma was determined by the pathologist and measured. The largest dimension was used for analysis and comparison. A complete pathologic response was identified as no residual invasive or in situ disease within the breast, and a non-complete pathologic response was identified as a residual tumor within the breast. To quantify the correlation between contrast-enhanced US, MRI, and pathologic findings, Spearman coefficients (r values) were calculated.
Results
Baseline Comparison of Tumor Size Before Starting NAC The age range of the patients included in the study was 24 to 64 years, with a median age of 51 years. Of the 30 patients included for analysis, 23 had both baseline contrast-enhanced US and MRI scans, whereas 7 patients had a baseline contrast-enhanced US scan only. The median tumor size (longest dimension) at baseline on conventional US imaging was 3.3 cm (25th and 75th percentiles, 2.4 and 4.7 cm); on contrast-enhanced US imaging, it was 3.1 cm (25th and 75th percentiles, 2.3 and 3.9 cm); and on MRI, it was 3.1 cm (25th and 75th percentiles, 2.5 and 4.5 cm). Spearman correlation showed tumor size on contrast-enhanced US had good agreement with both conventional US imaging and MRI (Figures 1 and 2) . One patient had a deep tumor that did not enhance on the baseline contrast-enhanced US scan but was seen on the conventional US scan and showed subthreshold enhancement on MRI. The deep location and low vascularity of the tumor likely contributed to its lack of enhancement on the contrastenhanced US scan. size of 1.7 cm (25th and 75th percentiles, 0.0 and 2.4 cm); and 21 had surgical pathologic reports for analysis, with a median tumor size of 1.5 cm (25th and 75th percentiles, 0.3 and 2.5 cm). One of the 21 patients with surgical pathologic reports did not receive either a post-NAC treatment contrast-enhanced US or MRI scan.
Comparison of Tumor
Fifteen of the 21 patients had both contrastenhanced US and MRI scans that could be compared with tumor size at surgery, whereas 3 patients had contrast-enhanced US scans only, and 2 patients had MRI only. Specifically, for this subset of 15 patients with post-NAC treatment contrast-enhanced US, MRI, and surgical pathologic findings, the median tumor sizes were 0.9 cm on contrast-enhanced US imaging (25th and 75th percentiles, 0.0 and 1.5 cm), 1.7 cm on MRI (25th and 75th percentiles, 0.0 and 2.4 cm), and 1.3 cm on surgical pathologic examinations (25th and 75th percentiles, 0.0 and 3.0 cm). After completion of NAC, there was less agreement by Spearman correlation between tumor size on contrast-enhanced US imaging compared with conventional US imaging and MRI (Figures 1 and 2) .
Eighteen patients had contrast-enhanced US tumor size compared with pathologic tumor size at surgery, with Spearman r 5 0.75 (P < .001). The mean deviation from the pathologic tumor size was 1.03 cm (95% confidence interval, 0.26-1.79 cm; P 5 .012), and the median deviation was 0.45 cm (range, 0.0-6.4 cm; Table 1 ).
Seventeen patients had MRI tumor size compared to pathologic tumor size at surgery, with Spearman r 5 0.42 (P 5 .095). The mean deviation from the pathologic tumor size was 1.05 cm (95% confidence interval, 0.48-1.62 cm; P 5 .002), and the median deviation was 0.8 cm (range, 0.0-3.5 cm; Table 1 ).
In the 15 patients with contrast-enhanced US and MRI scans after NAC, the incidence of undermeasurement and overmeasurement with imaging was evaluated. Eleven of the 15 tumors had contrast-enhanced US tumor measurements within 1 cm of the surgical size, whereas 10 tumors had MRI tumor measurements within 1 cm. Four tumors were undermeasured by greater than 1 cm on contrast-enhanced US imaging, whereas 2 tumors were undermeasured by greater than 1 cm on MRI. No tumors were overmeasured by greater than 1 cm on contrast-enhanced US imaging, whereas 3 tumors were overmeasured by greater than 1 cm on MRI (Table 1) . Of these 15 patients, 4 achieved a complete pathologic response with no residual invasive or in situ disease at surgical pathologic examination. Of the 4 patients with a complete pathologic response, both contrastenhanced US and MRI scans correctly showed no residual enhancing tumor in 3 patients (75.0% accuracy). In 1 patient, the contrast-enhanced US scan incorrectly showed a 9-mm minimally enhancing tumor. In another patient, MRI incorrectly showed a 2.4-cm area of nonmass enhancement.
Eleven of the 15 patients had a non-complete pathologic response, with residual invasive or in situ disease at surgery. Contrast-enhanced US and MRI scans both showed residual enhancing masses in 8 of the 11 patients (72.7% accuracy). Six of these 8 patients had correct reports by both modalities, whereas each modality correctly reported 2 patients that the other modality missed. With the remaining 1 patient, both contrast-enhanced US and MRI scans showed no residual enhancing mass when the patient had a 1.5-mm invasive cancer on surgical pathologic examination.
Correlation Between Quantitative Contrast-Enhanced US and MRI Parameters QLAB-derived quantitative contrast-enhanced US parameters (peak intensity in the tumor, peak intensity in the tumor minus background tissue, and wash-in slope in the tumor) were correlated with the highest CADstream-derived MRI contrast enhancement in the tumor at 1 minute. These specific parameters could be consistently obtained by the respective software and were thought to best represent tumor perfusion. The change in the quantitative parameters over time was investigated from baseline to after NAC for 11 of the 15 patients with comparable contrast-enhanced US and MRI data points. When the change over time was evaluated, none of the quantitative contrast-enhanced US parameters selected (peak intensity in the tumor, peak intensity in the tumor minus background, and wash-in Table 2 . The distribution of the quantitative contrast-enhanced US and MRI parameters is described in Table 3 . Even though Spearman correlation did not show good direct correlations for these quantitative parameters, the overall trend for all of the contrast-enhanced US and MRI quantitative parameters selected showed a decrease after NAC treatment was completed (Table 3) .
Tumor Necrosis
On imaging, as an indication of the treatment response and tumor cell death, tumor cell necrosis may be seen as cystic or nonenhancing spaces within the tumor. We wanted to see whether contrast-enhanced US imaging was comparable with MRI in estimating the amount of tumor necrosis. The radiologists reviewing the contrastenhanced US and MRI scans, who were blinded to the other modality, determined tumor necrosis subjectively. The amount of tumor necrosis was classified in quartiles as 0% to 25%, 26% to 50%, 51% to 75%, and 76% to 100%. Overall, of the 17 patients with both post-NAC contrast-enhanced US and MRI scans for comparison, there was not good concordance between the amount of tumor cell necrosis identified on contrast-enhanced US and MRI scans. This finding may have been because contrast-enhanced US tumor necrosis was assigned on the basis of a single slice of the tumor, while MRI tumor necrosis was based on multiple image slices through the tumor.
Discussion
Neoadjuvant chemotherapy decreases the tumor burden in patients who may be inoperable at diagnosis and increases the chance of breast-conserving surgery when mastectomy would be otherwise necessary. With imaging, physicians can assess the tumor response in vivo and determine whether the chemotherapy drugs are successful. Magnetic resonance imaging is generally superior to physical examination, mammography, and US imaging in evaluating the tumor response in the setting of NAC. 2, 7, 13 However, it has its own limitations, including expense, availability, contraindications to gadoliniumbased contrast agents (allergy and renal disease), and contraindications to the MRI scanner, such as the presence of pacemakers. Recent studies reported that repeated intravenous administration of gadoliniumbased contrast agents is associated with neuronal tissue deposition.
14 Finding a good imaging alternative to MRI would be beneficial to the patient.
To our knowledge, few studies have used contrastenhanced US to evaluate the tumor response in patients with breast cancer receiving NAC. Corcioni et al 12 showed a good correlation between contrast-enhanced US and MRI time/signal intensity curves and to pathologic responses in 16 patients. Cao et al 15 concluded that in 31 patients with breast cancer after NAC, contrast-enhanced US tumor size measurements were more accurate than conventional US measurements. Our study compared tumor sizes between contrastenhanced US imaging and MRI and ultimately with tumor sizes at surgery after NAC. In the 30 patients with baseline scans before NAC, there was a good correlation in the median tumor size (longest dimension) between contrast-enhanced and conventional US imaging and contrast-enhanced US imaging and MRI.
In post-NAC scans, the median tumor size for conventional US was 1.8 cm; for contrast-enhanced US, it was 1.1 cm; and for MRI, it was 1.7 cm. The median tumor size at surgery was 1.5 cm. Of the 20 patients who completed NAC and had surgery (15 patients with both contrast-enhanced US and MRI scans, 3 patients with contrast-enhanced US scans only, and 2 patients with MRI only), contrast-enhanced US imaging was more accurate than MRI in predicting the extent of the residual tumor. Contrast-enhanced US imaging had smaller mean and median deviations from tumor size at surgery than MRI.
In the 4 patients with a complete pathologic response and 11 patients with a non-complete pathologic response, contrast-enhanced US imaging was as accurate as MRI in correctly predicting the tumor response (Figures 3 and 4) . Both contrast-enhanced US and MRI scans correctly predicted 75.0% of the complete responders and 72.7% of the noncomplete responders. According to the Response Evaluation Criteria in Solid Tumors, version 1.1, 16 of the 11 patients with a non-complete pathologic response, 1 had progressive disease; 3 had stable disease; and 7 were partial responders. In the patient with progressive disease, contrast-enhanced US imaging shows a 6.7-cm residual tumor; MRI was not done; and an 8.5-cm residual invasive ductal carcinoma was seen at surgery.
Our results show that contrast-enhanced US is a promising imaging tool in the setting of NAC. Contrast-enhanced US findings correlate well with MRI findings and may be even more accurate in predicting residual tumor size after NAC. Magnetic resonance imaging has advantages over contrast-enhanced US imaging, since it can be used to evaluate additional multifocal and multicentric tumors and the contralateral breast. Contrast-enhanced US imaging can usually only evaluate a single target lesion per contrast agent bolus.
About 31 different quantitative MRI parameters have been investigated to predict the treatment response to NAC, but tumor size and tumor volume have been the most accurate so far. 2, 13, 17 We wanted to see what quantitative contrast-enhanced US parameters other than tumor size could be used to assess the tumor response, specifically the peak intensity in the tumor, peak intensity Figure 3 . Images from a 24-year-old woman with right breast hardness and a large lump found to be invasive ductal carcinoma at biopsy. A, Targeted right breast US imaging showed an irregular hypoechoic mass with angular margins measuring up to 6.3 cm. On the basis of her locally advanced disease seen clinically, she received NAC. B, At baseline before NAC, contrast enhanced US imaging showed an avidly enhancing tumor (green arrows) with tumor peak intensity on the time-intensity curve generated by the QLAB software. The ROI placed on adjacent normal breast tissue (yellow arrows) had a flat line on the time-intensity curve. The y-axis of the time-intensity graph corresponds to the intensity or mean echo (decibels), whereas the x-axis corresponds to the absolute time (seconds). C, Maximum-intensity projection contrast-enhanced MRI performed at baseline showed a multicentric enhancing tumor with mixed kinetics and areas of wash-out in all 4 quadrants of the right breast. After NAC was completed but before surgery, contrast-enhanced US and MRI scans were again performed. D, Contrast-enhanced US imaging showed no residual enhancing tumor. E, Maximum-intensity projection contrast-enhanced MRI performed after NAC was completed showed no residual enhancing tumor, only a few scattered nonspecific foci in the right breast. At the time of right mastectomy, this patient had no residual in situ or invasive tumor in the right breast, consistent with a complete pathologic response. There was concordance between the posttreatment contrastenhanced US and MRI studies with surgical pathologic findings. Images from a 50-year-old woman presenting with a right breast lump that was biopsy-proven infiltrating ductal carcinoma. A, Targeted right breast US imaging showed an oval hypoechoic mass with indistinct margins measuring up to 3.7 cm. B, At baseline before starting NAC, contrast-enhanced US imaging showed an avidly enhancing tumor (green arrows) with tumor peak intensity on the time-intensity curve generated by the QLAB software. The ROI was placed on adjacent normal breast tissue (yellow arrows), which had a flat line on the timeintensity curve. The y-axis of the time-intensity graph corresponds to the intensity or mean echo (decibels), whereas the x-axis corresponds to the absolute time (seconds). C, Axial post-contrast fat-saturated MRI at baseline showed an enhancing tumor with mixed kinetics in the right breast. After NAC was completed but before surgery, contrast-enhanced and MRI scans were again performed. D, Contrast-enhanced US imaging showed a 2.0-cm residual enhancing tumor with a time-intensity curve (blue arrows) that had rapid enhancement and wash-out. E, Maximum-intensity projection contrast-enhanced MRI performed after NAC was completed showed a decrease in the size of tumor to 2.0 cm with predominantly progressive kinetics. At the time of right lumpectomy, this patient had 1.5 cm of invasive tumor in the right breast, consistent with a non-complete pathologic response. Both the contrast-enhanced US and MRI studies predicted that there would be non-complete pathologic response at the time of surgery.
in the tumor minus background tissue, and wash-in slope in the tumor. We did not find good correlations between the interval changes in these parameters from the baseline scan to the posttreatment scan when compared with changes in MRI enhancement. However, all of the quantitative contrast-enhanced US parameters showed interval decreases in median values from the baseline to posttreatment scans. The lack of a good correlation between the quantitative contrast-enhanced US and MRI parameters was expected given the difference in sampling rates after contrast agent administration and the small sample size. Also, the contrast agents behave differently, with contrast-enhanced US microbubbles confined to the blood pool and MRI gadolinium-based contrast agents diffusing into interstitial tissue. Further studies are needed to determine whether these selected contrast-enhanced US parameters can assist in predicting a complete pathologic response after NAC.
Overall, the small number of patients limited our study, and studies on larger populations are needed to confirm our results. Although one of the patients did not show tumor enhancement on the baseline contrastenhanced US scan, which was likely related to the deep location or low vascularity of the tumor, our contrastenhanced US technique appears to be effective in identifying tumor vascularity and has a good correlation with MRI. The current literature and our experience with quantitative contrast-enhanced US parameters for characterizing breast cancers are still small and require more work to identify the parameters that are reproducible, consistent, and clinically valuable. All of the patients in our study had invasive ductal carcinoma, except for 1 patient with metaplastic carcinoma. We are hoping that future studies with more patients will allow us to investigate and compare the different subsets of invasive carcinomas, including lobular carcinomas.
In conclusion, our results show that contrastenhanced US imaging has an excellent correlation with MRI tumor size at baseline. After the completion of NAC, contrast-enhanced US imaging is comparable with MRI in predicting the extent of residual disease when compared with pathologic surgical specimens. Contrast-enhanced US imaging is as good as MRI in predicting a complete pathologic response and non-complete pathologic response. Therefore, contrast-enhanced US can potentially be used as an alternative to MRI in the evaluation of the tumor response in patients with breast cancer receiving NAC before to surgery. This approach would be especially useful in patients with contraindications to gadoliniumbased contrast agents or to entering the MRI scanner.
